Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.
about
Moving beyond Karnofsky and ECOG Performance Status Assessments with New TechnologiesPemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Factors influencing treatment selection and survival in advanced lung cancerFlexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.Assessing outcomes in palliative chemotherapy.Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study.Longitudinal patient-reported performance status assessment in the cancer clinic is feasible and prognostic.Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysisPrediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: a prospective study protocolCumulative scores based on plasma D-dimer and serum albumin levels predict survival in esophageal squamous cell carcinoma patients treated with transthoracic esophagectomyPrealbumin/CRP Based Prognostic Score, a New Tool for Predicting Metastasis in Patients with Inoperable Gastric Cancer.Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer.Supportive care in patients with advanced non-small-cell lung cancer.Performance status score: do patients and their oncologists agree?Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancerComparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancerThe systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer.Body Composition Features Predict Overall Survival in Patients With Hepatocellular CarcinomaAn inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.Inflammation as a validated prognostic determinant in carcinoma of unknown primary siteThe role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer.Congruence Between Latent Class and K-modes Analyses in the Identification of Oncology Patients with Distinct Symptom Experiences.Differences in Symptom Clusters Identified Using Ratings of Symptom Occurrence vs. Severity in Lung Cancer Patients Receiving Chemotherapy.Differences in symptom clusters identified using symptom occurrence rates versus severity ratings in patients with breast cancer undergoing chemotherapy.Continuous Activity Monitoring During Concurrent Chemoradiotherapy.Common and Distinct Characteristics Associated With Trajectories of Morning and Evening Energy in Oncology Patients Receiving Chemotherapy.Variability of performance status assessment between patients with hematologic malignancies and their physicians.Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies.Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.Cytokine Gene Polymorphisms Associated With Symptom Clusters in Oncology Patients Undergoing Radiation Therapy.Distinct Physical Function Profiles in Older Adults Receiving Cancer Chemotherapy.Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy.Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases.Changes in the Occurrence, Severity, and Distress of Symptoms in Patients With Gastrointestinal Cancers Receiving Chemotherapy.Prognostic value of scores based on malnutrition or systemic inflammatory response in patients with metastatic or recurrent gastric cancer.Patient-reported outcomes are associated with patient-oncologist agreement of performance status in a multi-ethnic Asian population.Glasgow Prognostic Score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding.
P2860
Q26749492-8FA19881-D1A4-47F0-B454-D0614388FCF0Q28081243-3D4CF3AC-B1B3-47FB-A6E0-7AC795AD8C84Q33611139-8FA4E3E7-38BD-4E6E-8C65-64EB7BF95428Q33783059-A809E144-A49E-4949-8615-721FD3789423Q34660752-1B0442F4-C41A-451C-B777-802E25F98E73Q35104573-38F41E64-6F78-4634-8F25-9E5175FDC64EQ35559782-DD69C889-6E43-42B6-8155-C8ED759C0703Q35996748-49921AA6-09C0-4DC9-9867-1FCF99022720Q36288003-36940CA3-8878-4AF3-855A-4A9855BB6014Q36370378-D78F99B2-A91C-488E-A896-62CD4BD034F2Q36454673-AC3A9B21-A134-45B7-A061-E11D161B5549Q36557940-09DA7E4D-A78A-4AFB-875A-6D2226B0AC09Q36613615-D8B179F6-DDA9-4E63-9036-5C6D36916890Q36613902-9F675EBF-9622-4068-8E91-129D91C72B06Q36648391-4571A077-A3C4-4D90-9152-D59D74FADB89Q36648445-A24B8C12-366C-4861-830F-ED74E3EE90A2Q36648454-7FF1E63E-13B6-4F35-AB29-B3A4F8BCF745Q36695064-B27B4F29-3F28-4EC0-8520-77DD5A4DFBF7Q36695683-2AECA485-A67F-4D81-B3CB-B49E75A47C9EQ36970515-8048F569-8CAA-47EB-BD44-F39632A6A6F2Q37152934-1F56CE01-43FD-4DCA-88AA-05B27CE2EA07Q37459607-DF885C21-BC35-4DFA-A3B6-95B4F14E40E0Q37605784-1E6A7B47-AE6E-4EBE-A412-160CD3A3DA96Q38599341-5E1FEF2A-2CF6-4F0D-B00A-DCC05D88E364Q38680518-E84567EB-D142-4072-81F3-42E1EF7724BEQ38686886-B972126D-4D15-4D66-A650-00FDECD82F31Q38884025-663A6ABB-56D0-46B4-8CD2-9ADB729AC167Q39034195-99CA5D7B-3F83-4AB3-A4D4-0A91E5015B57Q40118890-4040E5D9-A052-4062-9C14-C8073CBBAE5BQ40610972-C22461BA-8C3A-4521-A983-00BE44BB977CQ41517037-484401F7-002C-49BA-B715-311CA7265C4BQ46186348-D1253FCC-E84B-43B6-8276-1D8CEB02EADFQ46201472-8E065911-95CD-423E-ABDE-F476460667D8Q46309854-7B38478D-7AB8-47EB-B317-C1AAF3CDFF4AQ46384821-756292C7-97A2-4F3F-9136-F231A5FF2B44Q47196378-AA84EC45-2014-439C-B58E-3418B7683819Q47671686-D92EEB0E-6BCD-48CF-9199-F366CED8BFF7Q48061164-AA66272F-E1DB-4E22-BFFB-372B3E2F0B5DQ48071799-E8E238B3-ACA8-43A7-BC99-66E9F65B8A06Q52655174-D0D36D42-44E0-4D85-84DB-A0764653ABF6
P2860
Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Prognostic value of performanc ...... ed non-small cell lung cancer.
@ast
Prognostic value of performanc ...... ed non-small cell lung cancer.
@en
type
label
Prognostic value of performanc ...... ed non-small cell lung cancer.
@ast
Prognostic value of performanc ...... ed non-small cell lung cancer.
@en
prefLabel
Prognostic value of performanc ...... ed non-small cell lung cancer.
@ast
Prognostic value of performanc ...... ed non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
Prognostic value of performanc ...... ed non-small cell lung cancer.
@en
P2093
Hasegawa Y
Shimokata K
P2860
P2888
P304
P356
10.1054/BJOC.2001.2162
P407
P577
2001-11-01T00:00:00Z
P5875
P6179
1009527210